425: Akoya Biosciences Reports Q1 2025 Financial Results Amidst Quanterix Acquisition

Akoya Biosciences announced its Q1 2025 financial results, highlighting revenue of $16.6 million and progress in spatial biology adoption, while also noting a pending acquisition by Quanterix Corporation.

Summary

• Akoya Biosciences reported a revenue of $16.6 million for the first quarter of 2025, a 9.8% decrease compared to the $18.4 million in the same period last year.
• The gross margin improved to 59.3% in Q1 2025, up from 45.7% in the prior year period.
• Operating expenses decreased by 22.3% to $23.3 million, compared to $30.0 million in the prior year period.
• The operating loss improved by 37.9% to $13.4 million, compared to $21.6 million in the prior year period.
• Net cash used in operating activities decreased by $13.6 million to $7.2 million.
• The company had $27.5 million in cash, cash equivalents, and marketable securities as of March 31, 2025.
• Akoya's installed base increased by 12.0% year-over-year, reaching 1,359 instruments.
• Total publications citing Akoya's technology increased by 44.7% year-over-year, reaching 1,891.
• Due to the pending acquisition by Quanterix, Akoya will not host an earnings conference call or provide forward-looking guidance.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue decreased, there were improvements in gross margin, operating expenses, and operating loss. The pending acquisition by Quanterix adds uncertainty but also potential for future value creation.

Positives

• Gross margin improved significantly to 59.3% in Q1 2025.
• Operating expenses decreased by 22.3% to $23.3 million.
• Operating loss improved by 37.9% to $13.4 million.
• Net cash used in operating activities decreased by $13.6 million to $7.2 million.
• The installed base of instruments grew by 12.0% year-over-year to 1,359.
• Publications citing Akoya's technology increased by 44.7% year-over-year to 1,891.
• Akoya and Team SAMBAI announced the selection of PhenoCycler-Fusion as the foundational spatial proteomics platform for a landmark Cancer Grand Challenges-funded study.
• Akoya and the Singapore Translational Cancer Consortium (STCC) have partnered to deploy the PhenoCode Discovery IO60 panel in the SUPER study.

Negatives

• Akoya's Q1 2025 revenue was $16.6 million, a decrease of 9.8% compared to the previous year.

Risks

• The company faces broader macroeconomic and NIH funding uncertainty.
• The pending acquisition by Quanterix introduces uncertainty regarding future operations and strategy.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

In light of the pending acquisition by Quanterix Corporation, Akoya will not be hosting an earnings conference call or providing forward-looking guidance at this time.

Management Comments

• Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals, said Brian McKelligon, CEO of Akoya Biosciences.
• As we look ahead to combining forces with Quanterix, we are confident in the value-creating opportunities this integration brings uniting two leaders in proteomics to accelerate the future of precision medicine.

Industry Context

Akoya's focus on spatial biology and proteomics aligns with the growing trend towards precision medicine and personalized healthcare. The acquisition by Quanterix, another leader in proteomics, suggests a consolidation trend in the industry to offer more comprehensive solutions.

Comparison to Industry Standards

• It is difficult to compare Akoya's results directly to industry standards without knowing the specific growth rates and profitability metrics of its direct competitors in the spatial biology market.
• Companies like NanoString Technologies and 10x Genomics are also key players in the genomics and spatial analysis space, and their performance could provide a benchmark for Akoya's growth and market position.
• The 44.7% increase in publications citing Akoya's technology suggests a strong and growing influence in the scientific community, which is a positive indicator compared to competitors.

Stakeholder Impact

• Shareholders will be impacted by the pending acquisition by Quanterix.
• Employees face uncertainty during the integration process but may benefit from the combined company's growth.
• Customers may see enhanced product offerings and solutions from the combined company.
• The acquisition could impact suppliers and partners as the combined company streamlines its operations.

Next Steps

• The acquisition by Quanterix is pending and requires regulatory and shareholder approvals.
• Akoya will continue to focus on integrating with Quanterix and realizing the synergies of the combined company.

Key Dates

Keywords

Akoya Biosciences, Quanterix, Spatial Biology, Financial Results, Acquisition, PhenoCycler, PhenoImager, Proteomics, Cancer Research